Adiponectin is a protein hormone expressed by the ADIPOQ gene and was first discovered in human lipocytes in 1995. Adiponectin is known to be one of the most important hormones and has been called a “guardian angel” because of its various beneficial and essential physiological functions, including glucose homeostasis, anti-inflammation, fatty acid decomposition, and cardiovascular protection by alleviating insulin resistance. In patients with various intractable diseases, adiponectin hormone concentrations have been reported to be significantly lower than in ordinary persons, and following reports on active research into adiponectin function and disease associations, there is a demand for the development of treatment technology to restore the adiponectin hormone function.

Using innovative and scientific design technology, EncuraGen has developed active peptides that can function as a hormone by binding with receptors and replacing the adiponectin hormone. Of these, BHD1028 has been confirmed to exhibit outstanding efficacy in disease models such as Type 2 diabetes, obesity, and xerophthalmus, and the possibility of developing therapeutics for various refractory diseases is also being verified based on the physiological functions of adiponectin hormones.